Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The aim of this study is to evaluate the efficacy of Eravacycline in the treatment of patients with bacterial infection and to assess the pharmacokinetics of Eravacycline and to establish a population pharmacokinetic model of Eravacycline.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| Clinical remission rate | Completion of scheduled course of treatment; ≤14 days of treatment; treatment not restarted within 48 hours of discontinuation | At the end of treatment；2 weeks（estimated） |
| Microbiological efficacy | Evaluate at the end of treatment and at post-treatment (discharge) in patients who met all clinical evaluation criteria and who had positive bacteriologic cultures prior to treatment, and bacterial clearance was calculated using the results of post-treatment follow-up (discharge) as the primary endpoint of evaluation.Performing safety observation (including coagulation dysfunction and other adverse reactions) | From enrollment to the end of treatment at 28 days |
| Measure | Description | Time Frame |
|---|---|---|
| Develop Population Pharmacokinetic Model | Initial testing perform at first dose and steady-state testing perform at the seventh dose.Calculation of all-eravacycline fAUC using the linear trapezoidal method.Multiple regression analysis use to generate the best model equation for estimating the fAUC using the concentration of eravacycline at each sampling point in the modeling group as the independent variable and the fAUC as the dependent variable. |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
100 critically infected patients
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Lingai Pan | Contact | +8617708130236 | panlingai2004@163.com |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| From enrollment to the end of treatment at 28 days |